Sunitinib malate (sutent®), the small molecule inhibitor that targets receptor tyrosine kinases [36] profoundly inhibited PDGFRβ activation and downstream signaling cascade as indicated by inhibition of Akt and Erk phosphorylation in both the AI tumorspheres and the AD cells. This evidence concerns the gene NTRK1 and Alzheimer disease.